Periodic Reporting for period 1 - SINPAIN (A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis)
Berichtszeitraum: 2022-05-01 bis 2023-10-31
The contribution of SINPAIN to the management of OA focuses on three main aspects: 1) a product pipeline of safe, efficient and cost-effective therapies that could not only stop but reverse the course of the disease, 2) a new tool to support personalised diagnosis and treatment and 3) a comprehensive characterisation of the cells involved in OA’s pathogenesis. The new treatment combines novel RNA-based medicines that block molecular sources of inflammation and pain, an improved intraarticular hydrogel based on hyaluronic acid and smart delivery systems for anti-inflammatory drugs. If successful, SINPAIN technology will be instrumental in alleviating pain and slowing down disease progression for countless patients.
At the same time, the multidisciplinary team in SINPAIN is exerting in setting up optimal methods to find out the specific cells in the cartilage and synovia that send these inflammation and pain signals into the body using human knee sample from patients having prosthesis implant surgery. Furthermore, systems to study how different cell types interact in OA are being developed. Finally, a significant amount of healthy and osteoarthritic people have volunteered to have their knees imaged (magnetic resonance, computerised tomography and X-rays), information that is being used to identify anatomic features used in a machine learning tool to elaborate a new decision making to diagnose the disease more precisely.